Back to top
more

ProQR Therapeutics (PRQR)

(Delayed Data from NSDQ)

$1.99 USD

1.99
134,009

+0.13 (6.99%)

Updated Apr 19, 2024 04:00 PM ET

After-Market: $1.98 -0.01 (-0.50%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for PRQR

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

ProQR Therapeutics N.V. [PRQR]

Reports for Purchase

Showing records 1 - 20 ( 50 total )

Company: ProQR Therapeutics N.V.

Industry: Medical - Biomedical and Genetics

Record: 1

03/14/2024

Company Report

Pages: 6

Highlighting Axiomer Potential as Lead ADAR Programs Remain on Track to Enter Clinics

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: ProQR Therapeutics N.V.

Industry: Medical - Biomedical and Genetics

Record: 2

12/28/2023

Industry Report

Pages: 130

Genomic Medicine Deep Dive-Redrawing Frontiers at the Coding Level

Provider: H.C. Wainwright & Co., Inc.

Analyst: KAPOOR M

Price: 75.00

Research Provided by a Third Party

Company: ProQR Therapeutics N.V.

Industry: Medical - Biomedical and Genetics

Record: 3

11/08/2023

Company Report

Pages: 6

AX-1412 Might Unlock the Potential of EONS for Cardiovascular Diseases; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: ProQR Therapeutics N.V.

Industry: Medical - Biomedical and Genetics

Record: 4

08/07/2023

Company Report

Pages: 6

Platform Updates and Looking to the Future of Axiomer Pipeline; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: ProQR Therapeutics N.V.

Industry: Medical - Biomedical and Genetics

Record: 5

05/17/2023

Company Report

Pages: 6

Axiomer Platform Defines Next Chapter For RNA Therapeutic Focus; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: ProQR Therapeutics N.V.

Industry: Medical - Biomedical and Genetics

Record: 6

03/30/2023

Company Report

Pages: 6

Axiomer Clarity Sets Next Stages For RNA-Editing Platform; Reit Buy and PT to $5

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: ProQR Therapeutics N.V.

Industry: Medical - Biomedical and Genetics

Record: 7

11/10/2022

Company Report

Pages: 6

Axiomer RNA Platform Remains Focus-Initial Targets Anticipated Early 2023

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: ProQR Therapeutics N.V.

Industry: Medical - Biomedical and Genetics

Record: 8

08/15/2022

Company Report

Pages: 6

Strategic Focus Shifts to Axiomer RNA Platform-Targets on 2022 Horizon; PT to $1.50

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: ProQR Therapeutics N.V.

Industry: Medical - Biomedical and Genetics

Record: 9

08/05/2022

Company Report

Pages: 6

Axiomer Platform and Ultevursen Regulatory Discussions Can Define 2022 Progress

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: ProQR Therapeutics N.V.

Industry: Medical - Biomedical and Genetics

Record: 10

05/09/2022

Company Report

Pages: 6

Considerations Beyond ILLUMINATE Trial; Restructuring, Axiomer Clarity Expected 2H22; PT to $2

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: ProQR Therapeutics N.V.

Industry: Medical - Biomedical and Genetics

Record: 11

02/28/2022

Company Report

Pages: 7

Shifting Focus Beyond Sepofarsen-Upcoming 2022 Platform Catalysts

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: ProQR Therapeutics N.V.

Industry: Medical - Biomedical and Genetics

Record: 12

02/14/2022

Company Report

Pages: 7

Pivotal Phase 2/3 Sepofarsen Top Line Miss Shifts Strategic Focus; PT to $4

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: ProQR Therapeutics N.V.

Industry: Medical - Biomedical and Genetics

Record: 13

02/09/2022

Daily Note

Pages: 4

Considerations For Approaching Phase 2/3 Sepofarsen Top-Line

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: ProQR Therapeutics N.V.

Industry: Medical - Biomedical and Genetics

Record: 14

11/19/2021

Daily Note

Pages: 5

Sepofarsen Leads RNA Therapy Advancement - State of the Union

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: ProQR Therapeutics N.V.

Industry: Medical - Biomedical and Genetics

Record: 15

11/05/2021

Company Report

Pages: 7

Sepofarsen LCA-10 Readout Expected Near-Term; RNA Platform Broadens Reach

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: ProQR Therapeutics N.V.

Industry: Medical - Biomedical and Genetics

Record: 16

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for PRQR

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: ProQR Therapeutics N.V.

Industry: Medical - Biomedical and Genetics

Record: 17

09/09/2021

Daily Note

Pages: 5

Axiomer Collaboration Yields Opportunity for Broader RNA Editing Validation

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: ProQR Therapeutics N.V.

Industry: Medical - Biomedical and Genetics

Record: 18

08/06/2021

Company Report

Pages: 7

Steady As She Goes - RNA Therapy Platform Poised for Multiple Shots On Goal

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: ProQR Therapeutics N.V.

Industry: Medical - Biomedical and Genetics

Record: 19

05/10/2021

Company Report

Pages: 7

Our Thoughts on Forthcoming Data Readouts; Advancement Across RNA Pipeline

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: ProQR Therapeutics N.V.

Industry: Medical - Biomedical and Genetics

Record: 20

03/24/2021

Daily Note

Pages: 4

Positive STELLAR Trial Sets Stage for Registration; Initiation Expected YE21

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party